Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620670 | 0.92 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL14733125 | 0.92 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14733081 | 0.86 | — | — | |
| SCHEMBL14733120 | 0.84 | — | — | |
| SCHEMBL14733082 | 0.83 | — | — | |
| SCHEMBL439564 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL14733079 | 0.74 | LMNA (0.33) | LMNA | |
| SCHEMBL14733080 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL10418727 | 0.73 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8604968 | 0.71 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066716-A1 | ENERGETIC N-SUBSTITUTED 3, 3-DINITROAZETIDINE PLASTICIZER AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2017-03-09 | — | — | US | disclosed |
| US-20170066716-A1 | ENERGETIC N-SUBSTITUTED 3, 3-DINITROAZETIDINE PLASTICIZER AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2017-03-09 | — | — | US | disclosed |
| US-9573894-B1 | Energetic N-substituted 3, 3-dinitroazetidine plasticizer and preparation method thereof | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2017-02-21 | — | — | US | disclosed |
| US-9573894-B1 | Energetic N-substituted 3, 3-dinitroazetidine plasticizer and preparation method thereof | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2017-02-21 | — | — | US | disclosed |
| US-9227910-B2 | Gem-dinitro ester energetic material using esterification and preparation method thereof | AGENCY FOR DEFENCE DEVELOPMENT (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227910-B2 | Gem-dinitro ester energetic material using esterification and preparation method thereof | AGENCY FOR DEFENCE DEVELOPMENT (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9029591-B2 | Gem-dinitro ester compound as energetic material and preparation method thereof | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029591-B2 | Gem-dinitro ester compound as energetic material and preparation method thereof | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2015-05-12 | — | — | US | disclosed |
| US-20150119599-A1 | GEM-DINITRO ESTER ENERGETIC MATERIAL USING ESTERIFICATION AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20150119599-A1 | GEM-DINITRO ESTER ENERGETIC MATERIAL USING ESTERIFICATION AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20140121401-A1 | GEM-DINITRO ESTER COMPOUND AS ENERGETIC MATERIAL AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2014-05-01 | — | — | US | disclosed |
| US-20140121401-A1 | GEM-DINITRO ESTER COMPOUND AS ENERGETIC MATERIAL AND PREPARATION METHOD THEREOF | AGENCY FOR DEFENSE DEVELOPMENT (KR) | 2014-05-01 | — | — | US | disclosed |
| US-8664247-B2 | Acyclic organonitro compounds for use in treating cancer | RADIORX, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664247-B2 | Acyclic organonitro compounds for use in treating cancer | RADIORX, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130053418-A1 | ACYCLIC ORGANONITRO COMPOUNDS FOR USE IN TREATING CANCER | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053418-A1 | ACYCLIC ORGANONITRO COMPOUNDS FOR USE IN TREATING CANCER | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20090216049-A1 | Process and intermediates for the production of BDNPA and BDNPF and other bis(dinitroalkyl)acetals and formals | DIMENSION TECHNOLOGY CHEMICAL SYSTEMS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090216049-A1 | Process and intermediates for the production of BDNPA and BDNPF and other bis(dinitroalkyl)acetals and formals | DIMENSION TECHNOLOGY CHEMICAL SYSTEMS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1932817-A1 | Nitratoethyl nitroamine propellant for automobile safety systems | Nitrochemie Wimmis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119599-A1 | GEM-DINITRO ESTER ENERGETIC MATERIAL USING ESTERIFICATION AND PREPARATION METHOD THEREOF | GMNN, GEMIN5, GEMIN4 | ALDH1A1 300/4885LMNA 1399/4885 |
| US-20170066716-A1 | ENERGETIC N-SUBSTITUTED 3, 3-DINITROAZETIDINE PLASTICIZER AND PREPARATION METHOD THEREOF | NFE2L2, NQO1, NBAS | ALDH1A1 126/4885LMNA 3767/4885 |
| US-20090216049-A1 | Process and intermediates for the production of BDNPA and BDNPF and other bis(dinitroalkyl)acetals and formals | NPPA, NCF1, NOS2 | ALDH1A1 88/4885LMNA 571/4885 |
| US-20140121401-A1 | GEM-DINITRO ESTER COMPOUND AS ENERGETIC MATERIAL AND PREPARATION METHOD THEREOF | GMNN, GEMIN4, GEMIN5 | ALDH1A1 1210/4885LMNA 967/4885 |
| US-20130053418-A1 | ACYCLIC ORGANONITRO COMPOUNDS FOR USE IN TREATING CANCER | GMNN, OTC, OAT | ALDH1A1 1345/4885LMNA 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.